Savara Inc.

SVRA Healthcare Biotechnology

In the quarter to June 2026, EPS fell 14.3%, free cash flow fell 14.1% and total debt rose 1.54%, each against the same quarter a year earlier.

4.45 0.29 −6.12%
Market cap
$973.9M
P/E
0.0×
Fwd P/E
−3.9×
Dividend yield
—
F-score
n/a
Altman Z
−3.18
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
10.13 13.47 11.85 7.65
Net Debt/EBITDA
3.47 4.39 6.10 3.10
Debt/Equity
0.21 0.17 0.15 0.32
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.12) (0.13) (0.11) (0.10)
Book value per Share
0.57 0.70 0.91 0.44
Free Cash Flow
(29.97) (33.10) (25.06) (22.53)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates